Merkel Cell Carcinoma Therapeutic Update

Current Treatment Options in Oncology

Volumn 17, Issue 7, 2016, Pages

  Cassler, Nicole M ^a   Merrill, Dean ^b   Bichakjian, Christopher K ^c   Brownell, Isaac ^d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AKT; Avelumab; Cabozantinib; CM2B4; FDG PET; Idelalisib; Imatinib; MCV; Merkel cell carcinoma; MLN0128; mTOR; Neuroendocrine; Octreotide; Pazopanib; PD 1; PD L1; Pembrolizumab; PI3K; Polyomavirus; Vaccine; VP1

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; AVELUMAB; CABOZANTINIB; CARBOPLATIN; CHROMOGRANIN A; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DURVALUMAB; ETOPOSIDE; IDELALISIB; IMATINIB; INTERLEUKIN 12; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SAPANISERTIB; TICILIMUMAB; UNINDEXED DRUG; VINCRISTINE; BIOLOGICAL MARKER;

ADOPTIVE TRANSFER; BRACHYTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; DRUG FATALITY; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN SURGERY; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CARCINOMA, MERKEL CELL; DIAGNOSTIC IMAGING; METABOLISM; MULTIMODALITY CANCER THERAPY; PROCEDURES; SKIN NEOPLASMS;

BIOMARKERS; CARCINOMA, MERKEL CELL; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HUMANS; MOLECULAR TARGETED THERAPY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84975889685     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-016-0409-1     Document Type: Review

References (97)

1. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58(3):375–81. doi:10.1016/j.jaad.2007.11.020.
2. Paulson KG, Iyer JG, Blom A, Warton EM, Sokil M, Yelistratova L, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol. 2013;133(3):642–6. doi:10.1038/jid.2012.388.
3. Asgari MM, Sokil MM, Warton EM, Iyer J, Paulson KG, Nghiem P. Effect of host, tumor, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. JAMA Dermatol. 2014;150(7):716–23. doi:10.1001/jamadermatol.2013.8116. A single-institution study describing a negative prognostic impact of immune compromise and confirming prior observations that nodal MCC with unknown primary has a better prognosis than nodal disease with known primary.
4. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751–61. doi:10.1016/j.jaad.2010.02.056.
5. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4. doi:10.1245/s10434-010-0985-4.
6. Foote M, Veness M, Zarate D, Poulsen M. Merkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) disease. J Am Acad Dermatol. 2012;67(3):395–9. doi:10.1016/j.jaad.2011.09.009.
7. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100. doi:10.1126/science.1152586.
8. Fitzgerald TL, Dennis S, Kachare SD, Vohra NA, Wong JH, Zervos EE. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg. 2015;81(8):802–6.
9. Network NCC. Merkel cell carcinoma (version 1.2016). http://www.nccn.org/professionals/physician_gls/PDF/mcc.pdf. Accessed Jan 2016.
10. Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in Merkel cell carcinoma: a 15 year institutional experience and statistical analysis of 721 reported cases. Br J Dermatol. 2015. doi:10.1111/bjd.14240. This large retrospective review demonstrated no increased recurrence with adjuvant RT in the setting of negative SLNB.
11. Chan JK, Suster S, Wenig BM, Tsang WY, Chan JB, Lau AL. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol. 1997;21(2):226–34.
12. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23(10):2300–9. doi:10.1200/JCO.2005.02.329.
13. Schwartz JL, Griffith KA, Lowe L, Wong SL, McLean SA, Fullen DR, et al. Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol. 2011;29(8):1036–41. doi:10.1200/JCO.2010.33.4136.
14. Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol. 2014;70(4):637–43. doi:10.1016/j.jaad.2013.11.031. This study reinforced the utility of SLNB for tumors of any size and correlated the number of positive nodes with survival.
15. Ko JS, Prieto VG, Elson PJ, Vilain RE, Pulitzer MP, Scolyer RA, et al. Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of stage III patients. Mod Pathol. 2015. doi:10.1038/modpathol.2015.109.
16. Hawryluk EB, O’Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, et al. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women’s Cancer Center. J Am Acad Dermatol. 2013;68(4):592–9. doi:10.1016/j.jaad.2012.08.042.
17. Treglia G, Kakhki VR, Giovanella L, Sadeghi R. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis. Am J Clin Dermatol. 2013;14(6):437–47. doi:10.1007/s40257-013-0040-x.
18. Colgan MB, Tarantola TI, Weaver AL, Wiseman GA, Roenigk RK, Brewer JD, et al. The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma. J Am Acad Dermatol. 2012;67(6):1250–6. doi:10.1016/j.jaad.2012.03.018.
19. Peloschek P, Novotny C, Mueller-Mang C, Weber M, Sailer J, Dawid M, et al. Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol. 2010;73(2):317–23. doi:10.1016/j.ejrad.2008.10.032.
20. Kritikos N, Priftakis D, Stavrinides S, Kleanthous S, Sarafianou E. Nuclear medicine techniques in Merkel cell carcinoma: a case report and review of the literature. Oncol Lett. 2015;10(3):1610–6. doi:10.3892/ol.2015.3377.
21. Liu J, Larcos G, Howle J, Veness M. Lack of clinical impact of (18) F-fluorodeoxyglucose positron emission tomography with simultaneous computed tomography for stage I and II Merkel cell carcinoma with concurrent sentinel lymph node biopsy staging: a single institutional experience from Westmead Hospital, Sydney. Australas J Dermatol. 2015. doi:10.1111/ajd.12400.
22. Fantini F, Johansson O. Neurochemical markers in human cutaneous Merkel cells. An immunohistochemical investigation. Exp Dermatol. 1995;4(6):365–71.
23. Buder K, Lapa C, Kreissl MC, Schirbel A, Herrmann K, Schnack A, et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer. 2014;14:268. doi:10.1186/1471-2407-14-268.
24. Epstude M, Tornquist K, Riklin C, di Lenardo F, Winterhalder R, Hug U, et al. Comparison of (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized Merkel cell carcinoma. Clin Nucl Med. 2013;38(4):283–4. doi:10.1097/RLU.0b013e318281658e.
25. Garneski KM, Warcola AH, Feng Q, Kiviat NB, Leonard JH, Nghiem P. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol. 2009;129(1):246–8. doi:10.1038/jid.2008.229.
26. Spurgeon ME, Lambert PF. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology. 2013;435(1):118–30. doi:10.1016/j.virol.2012.09.029.
27. Rodig SJ, Cheng J, Wardzala J, DoRosario A, Scanlon JJ, Laga AC, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest. 2012;122(12):4645–53. doi:10.1172/JCI64116.
28. Matsushita M, Nonaka D, Iwasaki T, Kuwamoto S, Murakami I, Kato M, et al. A new in situ hybridization and immunohistochemistry with a novel antibody to detect small T-antigen expressions of Merkel cell polyomavirus (MCPyV). Diagn Pathol. 2014;9:65. doi:10.1186/1746-1596-9-65.
29. Paulson KG, Carter JJ, Johnson LG, Cahill KW, Iyer JG, Schrama D, et al. Antibodies to Merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in Merkel cell carcinoma patients. Cancer Res. 2010;70(21):8388–97. doi:10.1158/0008-5472.CAN-10-2128.
30. Samimi M, Molet L, Fleury M, Laude H, Carlotti A, Gardair C, et al. Prognostic value of antibodies to Merkel cell polyomavirus T-antigens and VP1 protein in Merkel cell carcinoma patients. Br J Dermatol. 2015. doi:10.1111/bjd.14313.
31. Touzé A, Le Bidre E, Laude H, Fleury MJ, Cazal R, Arnold F, et al. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J Clin Oncol. 2011;29(12):1612–9. doi:10.1200/JCO.2010.31.1704.
32. Sihto H, Kukko H, Koljonen V, Sankila R, Böhling T, Joensuu H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res. 2011;17(14):4806–13. doi:10.1158/1078-0432.CCR-10-3363.
33. Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 2015;75(24):5228–34. doi:10.1158/0008-5472.CAN-15-1877.
34. Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget. 2015. doi:10.18632/oncotarget.6494. Whole exome sequencing identifies that MCV-negative MCCs have a higher mutational burden than MCV-positive tumors.
35. Harms PW, Vats P, Verhaegen ME, Robinson DR, Wu YM, Dhanasekaran SM, et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res. 2015;75(18):3720–7. doi:10.1158/0008-5472.CAN-15-0702. Whole exome sequencing identifies that MCV-negative MCCs have a higher mutational burden than MCV-positive tumors.
36. Rush Z, Fields RC, Lee N, Brownell I. Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Rev Dermatol. 2011;6(4):395–404. doi:10.1586/edm.11.40.
37. Leonard JH, Ramsay JR, Kearsley JH, Birrell GW. Radiation sensitivity of Merkel cell carcinoma cell lines. Int J Radiat Oncol Biol Phys. 1995;32(5):1401–7. doi:10.1016/0360-3016(94)00610-W.
38. Lok B, Khan S, Mutter R, Liu J, Fields R, Pulitzer M, et al. Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer. 2012;118(16):3937–44. doi:10.1002/cncr.26738.
39. Harrington C, Kwan W. Radiotherapy and conservative surgery in the locoregional management of Merkel cell carcinoma: the British Columbia Cancer Agency experience. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4812-9.
40. Veness M, Foote M, Gebski V, Poulsen M. The role of radiotherapy alone in patients with Merkel cell carcinoma: reporting the Australian experience of 43 patients. Int J Radiat Oncol Biol Phys. 2010;78(3):703–9. doi:10.1016/j.ijrobp.2009.08.011.
41. Mortier L, Mirabel X, Fournier C, Piette F, Lartigau E. Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol. 2003;139(12):1587–90. doi:10.1001/archderm.139.12.1587.
42. Jouary T, Leyral C, Dreno B, Doussau A, Sassolas B, Beylot-Barry M, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol. 2012;23(4):1074–80. doi:10.1093/annonc/mdr318.
43. Bichakjian CK, Harms KL, Schwartz JL. Selective use of adjuvant therapy in the management of Merkel cell carcinoma. JAMA Oncol. 2015;1(8):1162–3. doi:10.1001/jamaoncol.2015.1503.
44. Grotz TE, Joseph RW, Pockaj BA, Foote RL, Otley CC, Bagaria SP, et al. Negative sentinel lymph node biopsy in Merkel cell carcinoma is associated with a low risk of same-nodal-basin recurrences. Ann Surg Oncol. 2015;22(12):4060–6. doi:10.1245/s10434-015-4421-7. A single-institution study suggesting that regional RT can be avoided if SLNB is negative.
45. Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer. 2013;2013:327150. doi:10.1155/2013/327150.
46. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000;18(12):2493–9.
47. Iyer JG, Parvathaneni U, Gooley T, Miller NJ, Markowitz E, Blom A, et al. Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med. 2015;4(8):1161–70. doi:10.1002/cam4.458. This study used SFRT as a successful alternative to chemotherapy for palliation in advanced disease.
48. Garibyan L, Cotter SE, Hansen JL, Noell C, Dorosario A, O’Farrell DA, et al. Palliative treatment for in-transit cutaneous metastases of Merkel cell carcinoma using surface-mold computer-optimized high-dose-rate brachytherapy. Cancer J. 2013;19(4):283–7. doi:10.1097/PPO.0b013e31829e3566.
49. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239.
50. Lyngaa R, Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, et al. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin Cancer Res. 2014;20(7):1768–78. doi:10.1158/1078-0432.CCR-13-2697.
51. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54–63. doi:10.1158/2326-6066.CIR-13-0034.
52. Avelumab in subjects with Merkel cell carcinoma (JAVELIN Merkel 200). National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02155647. Accessed Jan 2016.
53. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–93. doi:10.1158/1078-0432.CCR-14-2607.
54. Nghiem P, Bhatia S, Daud A, Friedlander P, Kluger H, Kohrt H et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma [abstract]. The European Cancer Congress; September 27; Vienna, Austria. 2015. This early study demonstrated exceptionally high initial response rates.
55. Pembrolizumab in treating patients with advanced Merkel cell cancer. National Institutes of Health. https://clinicaltrials.gov/show/NCT02267603. Accessed Jan 2016.
56. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30. doi:10.1016/S1470-2045(15)70122-1.
57. Adjuvant therapy of completely resected Merkel cell carcinoma with 3 mg/kg BW ipilimumab (Yervoy®) versus observation (ADMEC). National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02196961. Accessed Jan 2016.
58. Valsecchi ME. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270. doi:10.1056/NEJMc1509660#SA1.
59. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17. doi:10.1056/NEJMoa1414428.
60. A phase 1/2 study of in situ vaccination with tremelimumab and IV durvalumab plus polyICLC in subjects with advanced, measurable, biopsy-accessible cancers. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02643303. Accessed Jan 2016.
61. Sihto H, Böhling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, et al. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Cancer Res. 2012;18(10):2872–81. doi:10.1158/1078-0432.CCR-11-3020.
62. Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, et al. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am J Clin Pathol. 2014;142(4):452–8. doi:10.1309/AJCPIKDZM39CRPNC.
63. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol. 2011;29(12):1539–46. doi:10.1200/JCO.2010.30.6308.
64. Schmidinger M, Hejna M, Zielinski CC. Aldesleukin in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2004;4(6):957–80. doi:10.1586/14737140.4.6.957.
65. Viral oncoprotein targeted autologous T cell therapy for Merkel cell carcinoma. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT01758458. Accessed Jan 2016.
66. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7. doi:10.1158/1078-0432.CCR-11-0116.
67. Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014;2(1):27–36. doi:10.1158/2326-6066.CIR-13-0087.
68. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002;5(6):668–75. doi:10.1006/mthe.2002.0601.
69. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5896–903. doi:10.1200/JCO.2007.15.6794.
70. IL-12 gene and in vivo electroporation-mediated plasmid DNA vaccine therapy in patients with Merkel cell cancer. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT01440816. Accessed Jan 2016.
71. Hafner C, Houben R, Baeurle A, Ritter C, Schrama D, Landthaler M, et al. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One. 2012;7(2), e31255. doi:10.1371/journal.pone.0031255.
72. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012;18(5):1227–36. doi:10.1158/1078-0432.CCR-11-2308.
73. Shiver MB, Mahmoud F, Gao L. Response to idelalisib in a patient with stage IV Merkel-cell carcinoma. N Engl J Med. 2015;373(16):1580–2. doi:10.1056/NEJMc1507446.
74. Iwasaki T, Matsushita M, Nonaka D, Kuwamoto S, Kato M, Murakami I, et al. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas. Hum Pathol. 2015;46(2):210–6. doi:10.1016/j.humpath.2014.07.025.
75. Kannan A, Lin Z, Shao Q, Zhao S, Fang B, Moreno MA, et al. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth. Oncotarget. 2015. doi:10.18632/oncotarget.5878.
76. Dose escalation study of MLN0128 in subjects with advanced malignancies. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT01058707. Accessed Jan 2016.
77. MLN0128 in recurrent/metastatic Merkel cell carcinoma. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02514824. Accessed Jan 2016.
78. Brunner M, Thurnher D, Pammer J, Geleff S, Heiduschka G, Reinisch CM, et al. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod Pathol. 2008;21(7):876–84. doi:10.1038/modpathol.2008.63.
79. Davids MS, Davids M, Charlton A, Ng SS, Chong ML, Laubscher K, et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol. 2009;27(26):e97–100. doi:10.1200/JCO.2009.21.8149.
80. A trial of pazopanib for Merkel cell skin cancer (UKMCC-01). Cancer Research UK. http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-pazopanib-for-merkel-cell-carcinoma-ukmcc-01. Accessed Jan 2016.
81. Cabozantinib in recurrent/metastatic Merkel cell carcinoma. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02036476. Accessed Jan 2016.
82. Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, et al. A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331). Am J Clin Oncol. 2010;33(5):495–9. doi:10.1097/COC.0b013e3181b9cf04.
83. Loader DE, Feldmann R, Baumgartner M, Breier F, Schrama D, Becker JC, et al. Clinical remission of Merkel cell carcinoma after treatment with imatinib. J Am Acad Dermatol. 2013;69(4):e181–3. doi:10.1016/j.jaad.2013.03.042.
84. Kratochwil C, Giesel FL, López-Benítez R, Schimpfky N, Kunze K, Eisenhut M, et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16(10):2899–905. doi:10.1158/1078-0432.CCR-10-0004.
85. Pool SE, Kam BL, Koning GA, Konijnenberg M, Ten Hagen TL, Breeman WA, et al. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. Cancer Biother Radiopharm. 2014;29(4):179–87. doi:10.1089/cbr.2013.1552.
86. Limouris GS, Chatziioannou A, Kontogeorgakos D, Mourikis D, Lyra M, Dimitriou P, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35(10):1827–37. doi:10.1007/s00259-008-0779-0.
87. Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):179–91. doi:10.1016/j.hoc.2015.09.009.
88. 177Lutetium-DOTA-octreotate therapy in somatostatin receptor-expressing neuroendocrine neoplasms. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT01237457. Accessed Jan 2016.
89. A phase I, exploratory, intra-patient dose escalation study to investigate the preliminary safety, pharmacokinetics, and anti-tumor activity of pasireotide (SOM230). National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT01652547. Accessed Jan 2016.
90. Treatment of unresectable and/or metastatic Merkel cell carcinoma by somatostatine analogues. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02351128. Accessed Jan 2016.
91. Gaiser MR, Daily K, Hoffmann J, Brune M, Enk A, Brownell I. Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers. Oncotarget. 2015;6(28):26472–82. doi:10.18632/oncotarget.4500.
92. Blom A, Bhatia S, Pietromonaco S, Koehler K, Iyer JG, Nagase K, et al. Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma. J Am Acad Dermatol. 2014;70(3):449–55. doi:10.1016/j.jaad.2013.10.051.
93. Zeng Q, Gomez BP, Viscidi RP, Peng S, He L, Ma B, et al. Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine. 2012;30(7):1322–9. doi:10.1016/j.vaccine.2011.12.072.
94. Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF. Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen. Cell Biosci. 2013;3(1):29. doi:10.1186/2045-3701-3-29.
95. Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys. 2014;88(5):986–97. doi:10.1016/j.ijrobp.2013.08.035.
96. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013;1(2):92–8. doi:10.1158/2326-6066.CIR-13-0082.
97. Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, et al. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res. 2014;2(11):1071–9. doi:10.1158/2326-6066.CIR-14-0005.